Efficacy and Safety of Low Dose, Short Course Eltrombopag in Management of DF and DHF

dc.contributor.authorRahman, Md. Mobinuren_US
dc.contributor.authorRahman, Mizanuren_US
dc.contributor.authorAkhtar, Salinaen_US
dc.contributor.authorNahar, Kamrunen_US
dc.contributor.authorFattah, Abu Umar Alen_US
dc.date.accessioned2023-07-21T11:25:42Z
dc.date.available2023-07-21T11:25:42Z
dc.date.issued2022-06
dc.description.abstractBackground: Dengue is the most widespread aedes mosquito borne viral disease which infects more than 50 million people every year. The clinical symptoms of dengue may vary from mild fever to life-threatening incidents. Eltrombopag, a non-peptide, oral TPO-R agonist, small molecular weight is quandaries with the transmembrane domain of a TPO receptor and persuades the Janus Kinase/Signal transducer and activator of transcription pathway, with a significant rise in platelet production.Material & Methods:This study was a cross-sectional observational study which was conducted at Tairunnesa Memorial Medical College and Hospital (TMMCH), Gazipur and Shin Shin Japan Hospital, Uttara, Dhaka. The study was conducted in between July 2021- December 2021. The sample size for this study was 100.Results:The mean age in group 1 was 25� in group 2 29�and in control group 29� The mean Baseline PLT * 109 /L for group 1 was 57�, for group 2, 51� and for control group 54�. Mean of systolic baseline BP (mmHg) for group 1 was 103.55� 5.04 for group 2 was 105.38�.34 and for control group was 101.97�28 and followed by the mean of diastolic baseline BP (mmHg) was 72.83�56, 72.84�.93 and 71.97�75. AEs was found in 4(12.1%) cases of group 1 where in group 2 it was 2(5.9%) and in control group was 3(9.1%). In day 7, the recovery rate of group 1 was 93.9% and in group 2 the recovery rate was 94.1%.Conclusions:Dengue is a vector-borne viral disease which needs medical assistance because it may lead to life-threatening outcome. Eltrombopag can be considered as a therapeutic option to increase the PLT counts in DF and DHF patients in the management of thrombocytopenia.en_US
dc.identifier.affiliationsAssociate professor, Department of Medicine, Tairunnessa Memorial Medical College & Hospital, Gazipur, Bangladesh. Email: rmobinur7@gmail.com., Orcid ID: 0000-0002-7395-4687en_US
dc.identifier.affiliationsProfessor (CC), Department of Medicine, Tairunnessa Memorial Medical College & Hospital, Gazipur, Bangladesh. Email: mnmch14@yahoo.com, Orcid ID: 0000-0002-6295-5211en_US
dc.identifier.affiliationsProfessor (CC), Department of Physiology, Sapporo Dental College, Uttara model town, Dhaka, Bangladesh. Email: akhtar.salina2020@gmail.com, Orcid ID: 0000-0001-6330-2979en_US
dc.identifier.affiliationsConsultant, Department of Radiology and Imaging, Popular diagnostic Centre, Mirpur, Dhaka, Bangladesh. Email: drkamrunnahar1234@gmail.com, Orcid ID: 0000-0002-8406-4479en_US
dc.identifier.affiliationsAssistant Registrar, Department of Medicine, Tairunnessa Memorial Medical College & Hospital, Gazipur, Bangladesh. Email: abufattah006@gmail.com, Orcid ID: 0000-0002-9954-4360en_US
dc.identifier.citationRahman Md. Mobinur, Rahman Mizanur, Akhtar Salina, Nahar Kamrun, Fattah Abu Umar Al. Efficacy and Safety of Low Dose, Short Course Eltrombopag in Management of DF and DHF. Annals of International Medical and Dental Research. 2022 Jun; 8(3): 32-39en_US
dc.identifier.issn2395-2822
dc.identifier.issn2395-2814
dc.identifier.placeIndiaen_US
dc.identifier.urihttps://imsear.searo.who.int/handle/123456789/219973
dc.languageenen_US
dc.publisherScholars Publisheren_US
dc.relation.issuenumber3en_US
dc.relation.volume8en_US
dc.source.urihttps://doi.org/10.53339/aimdr.2022.8.3.5en_US
dc.subjectDengue feveren_US
dc.subjectDengue Haemorrhagic Feveren_US
dc.subjectEltrombopagen_US
dc.titleEfficacy and Safety of Low Dose, Short Course Eltrombopag in Management of DF and DHFen_US
dc.typeJournal Articleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
AIMDR2022v8n3p32.pdf
Size:
175.33 KB
Format:
Adobe Portable Document Format